| 000 | 01866 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515071753.0 | ||
| 264 | 0 | _c20070918 | |
| 008 | 200709s 0 0 eng d | ||
| 022 | _a0085-2538 | ||
| 024 | 7 |
_a10.1038/sj.ki.5002362 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLogar, C M | |
| 245 | 0 | 0 |
_aDarbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. _h[electronic resource] |
| 260 |
_bKidney international _cAug 2007 |
||
| 300 |
_a489-98 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aAntibodies |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aAutoantibodies |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aDarbepoetin alfa |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aErythropoietin _xanalogs & derivatives |
| 650 | 0 | 4 |
_aGlomerulonephritis _xcomplications |
| 650 | 0 | 4 |
_aGlomerulosclerosis, Focal Segmental _xetiology |
| 650 | 0 | 4 |
_aJanus Kinase 2 _xmetabolism |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aPodocytes _xdrug effects |
| 650 | 0 | 4 |
_aProtective Agents _xpharmacology |
| 650 | 0 | 4 |
_aProteinuria _xetiology |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-akt _xmetabolism |
| 650 | 0 | 4 |
_aPuromycin Aminonucleoside _xpharmacology |
| 650 | 0 | 4 |
_aReceptors, Erythropoietin _xdrug effects |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aTransforming Growth Factor beta1 _xmetabolism |
| 650 | 0 | 4 | _aUltraviolet Rays |
| 700 | 1 | _aBrinkkoetter, P T | |
| 700 | 1 | _aKrofft, R D | |
| 700 | 1 | _aPippin, J W | |
| 700 | 1 | _aShankland, S J | |
| 773 | 0 |
_tKidney international _gvol. 72 _gno. 4 _gp. 489-98 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.ki.5002362 _zAvailable from publisher's website |
| 999 |
_c17093169 _d17093169 |
||